Mode
Text Size
Log in / Sign up
Phase 2 N=5 Randomized Treatment

'TOTAL' (Tracheal Occlusion To Accelerate Lung Growth) Trial

Hernia · Hernia, Diaphragmatic · Hernia, DIaphragmatic, Congenital · Pathological Conditions, Anatomical · Congenital Abnormalities

Enrolled (actual)
5
Serious AEs
0.0%
Results posted
Jun 2022
Primary outcome: Primary: Proportion of Neonate Survival at Discharge From Hospital — 1; 3 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
GoldBal2 detachable balloon (Device); Baltaccidbpe100 Delivery Catheter (Device); Standardized postnatal care (Other)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
Michael A Belfort
Primary completion
Oct 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Proportion of Neonate Survival at Discharge From Hospital
1; 3
PRIMARY
Participants Requiring Supplemental Oxygen
1; 1
SECONDARY
Grade of Oxygen Dependency
0; 1; 0; 0; 1; 1
SECONDARY
Occurrence of Severe Pulmonary Hypertension
2; 2
SECONDARY
ECMO (Extracorporeal Membrane Oxygenation) Support
1; 2
SECONDARY
CDH Defect Size
0; 0; 0; 1; 2; 1
SECONDARY
Number of Days in the NICU
39; 53
SECONDARY
Ventilatory Support
18; 21
SECONDARY
Number of Subjects With Periventricular Leukomalacia (PVL)
0; 0
SECONDARY
Neonatal Sepsis
1; 0
SECONDARY
Intraventricular Hemorrhage
0; 0
SECONDARY
Retinopathy of Prematurity
0; 0
SECONDARY
Days to Full Enteral Feeding
27; 29.5
SECONDARY
Gastroesophageal Reflux
1; 0
SECONDARY
CDH (Congenital Diaphragmatic Hernia) Surgery Repair
1; 2.5
SECONDARY
Use of Patch in CDH Repair
2; 2
SECONDARY
Survival
1; 3

Summary

This trial will test whether temporary fetoscopic endoluminal tracheal occlusion (FETO) rather than expectant management during pregnancy, followed by standardized postnatal management, increases survival at discharge and decreases oxygen need at 6 months in case of survival till discharge.

Eligibility Criteria

Inclusion Criteria

  • Patients aged 18 years or more, who are able to consent,
  • Singleton pregnancy,
  • Chromosomally normal fetus,
  • Gestation at randomization prior to 31 weeks plus 5 days or so that occlusion is done at the latest on 31 weeks plus 6 days,
  • Fetus is estimated to have moderate pulmonary hypoplasia, defined prenatally as:
  • O/E LHR 25-34.9% (included; irrespective of the position of the liver) • O/E LHR 35-44.9% (included) with intrathoracic liver herniation as determined by ultrasound or MRI.

The O/E LHR will be determined by the FETO centers as follows:

  • Measurement of the contralateral lung area preferentially by the tracing method at the 4-chamber view of the heart; if by other method adjusted normative ranges must be used.
  • Measurement of the head circumference at the standard biparietal view of the head
  • The observed lung area: calculation of the LHR as the ratio of the measurements of the lung area to head circumference
  • The expected lung area is the lung area of a normal gestational age match, as determined by the head circumference of the index case in a normogram established for the same measurement method (tracing method in this case). A calculator for this will be available on the website of the study.
  • Calculation of the observed over expected lung area,
  • Acceptance of randomization and the consequences for the further management during pregnancy and thereafter, this includes the required observation following FETO surgery, which lasts up to 4 weeks after balloon is in place,
  • The patients must undertake the responsibility for either remaining close to, or at the FETO center, or being able to travel swiftly and within acceptable time interval to the FETO center until the balloon is removed. Intended postnatal treatment center must subscribe to suggested guidelines for "standardized postnatal treatment," and
  • Provide written consent to participate.
  • Fetus with no major anomalies that would impact the clinical course or outcomes.

Exclusion Criteria

  • Maternal contraindication to fetoscopic surgery or severe medical condition in pregnancy that make fetal intervention risky,
  • Technical limitations precluding fetoscopic surgery, such as severe maternal obesity, uterine fibroids or potentially others, not anticipated at the time of writing this protocol,
  • Preterm labor, cervix shortened (<15 mm at randomization) or uterine anomaly strongly predisposing to preterm labor, placenta previa,
  • Patient age less than 18 years,
  • Psychosocial ineligibility, precluding consent,
  • Diaphragmatic hernia: right-sided or bilateral, major anomalies, isolated left-sided outside the O/E LHR limits for the inclusion criteria, and
  • Patient refusing randomization, to comply with required 4-week observation after balloon placement, or to comply with return to FETO center during the time period the airways are occluded or for elective removal of the balloon.
  • Patient allergic to latex.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02875860). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search